PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors
A Phase 1/2 Biomarker-Guided Platform Study of Allogeneic Donor-Derived Single-Target or Dual-Target CAR-NK Cell Therapy Selected by Tumor Antigen Profiling (Liquid Biopsy and/or Tissue Biopsy) in Participants With Advanced Solid Tumors
Beijing Biotech
60 participants
Mar 2, 2026
INTERVENTIONAL
Conditions
Summary
This Phase 1/2, open-label, biomarker-guided platform study evaluates the safety, tolerability, and preliminary anti-tumor activity of banked allogeneic donor-derived chimeric antigen receptor natural killer (CAR-NK) cells in adults with advanced solid tumors. During screening, tumor antigen profiling is performed using tissue biopsy and/or liquid biopsy (circulating tumor DNA and/or circulating tumor cells). Participants are assigned to receive either a single-target CAR-NK product (matched to the dominant tumor antigen) or a dual-target CAR-NK product (matched to two co-expressed antigens) to reduce the risk of antigen escape.
Eligibility
Inclusion Criteria9
- Age 18 to 75 years at the time of consent.
- Histologically or cytologically confirmed advanced or metastatic solid tumor that is refractory to, relapsed after, or intolerant of standard therapy, or for which no standard therapy exists.
- At least 1 measurable lesion per RECIST v1.1.
- Tumor antigen positivity documented by tissue biopsy and/or liquid biopsy using a protocol-specified assay; for dual-target cohort: co-expression of both antigens above threshold.
- ECOG performance status 0-1.
- Adequate organ function (hematologic, renal, hepatic) as defined by protocol labs.
- Ability to undergo lymphodepleting chemotherapy (if required) and receive IV cell infusion.
- Negative pregnancy test for individuals of childbearing potential; agreement to use effective contraception during study participation and for a protocol-defined period after infusion.
- Willingness to provide baseline blood samples and, when feasible, tumor biopsy for biomarker analyses.
Exclusion Criteria10
- Active, uncontrolled infection, including uncontrolled bacterial, fungal, or viral infection.
- Known uncontrolled HIV infection; active hepatitis B or hepatitis C with evidence of active replication (per local testing).
- Clinically significant cardiovascular disease (e.g., recent myocardial infarction, uncontrolled arrhythmia) that would increase risk from lymphodepletion or infusion.
- Active central nervous system (CNS) metastases that are symptomatic or require escalating steroids.
- (Stable treated CNS disease may be allowed per protocol.)
- Current systemic immunosuppressive therapy (e.g., >10 mg/day prednisone equivalent) within a protocol-defined window prior to lymphodepletion.
- Prior gene-modified cellular therapy within 3 months or any prior therapy that, in the investigator's judgment, would confound safety evaluation.
- Prior allogeneic hematopoietic stem cell transplant within 6 months, or active graft-versus-host disease.
- Pregnant or breastfeeding.
- Any condition that, in the investigator's opinion, would interfere with study participation, compliance, or interpretation of results.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
single-target CAR-NK cell infusion, IV
dual-target CAR-NK cell infusion, IV
fludarabine + cyclophosphamide
low-dose IL-2 or IL-15 agonist
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07510828